Sign in
← Compounds

Acarbose

off-label Rx · medium oversightFDA-approved

Alpha-glucosidase inhibition; post-prandial glucose

Summary

Alpha-glucosidase inhibitor; blunts post-prandial glucose. Used off-label for metabolic/longevity goals.

How it works

  • Delays intestinal carbohydrate digestion
  • ↓ post-prandial glucose

Dosing

  • unit: mg
    frequency: with meals
    high dose: 100
    standard dose: 50
    administration route: Oral

Cycling

  • Continuous

Side effects

common: ["Flatulence, GI (dose-related)"]
warnings: []

Verified citations

2 · PubMed-checked
  • Effects of alpha-glucosidase-inhibiting drugs on postprandial glucose and insulin: meta-analysis.clinicalPMID 33658478 ↗
  • Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.reviewPMID 19275550 ↗

Used for

No condition evidence rows yet.

Legal / compounding

FDA-approved

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.